In what situations, if any, would you recommend NALIRIFOX over FOLFIRINOX for first-line treatment of patients with unresectable pancreatic cancer?

Given the currently available information, I would not use NALIRIFOX instead of mFOLFIRINOX in any situation.

My reasons for this are:

1. mFOLFIRINOX has been the standard of care for the treatment of metastatic and unresectable pancreatic cancer in patients who can tolerate this regimen for over a deca...

Fully agree with answers/comments above that with current evidence I cant see any scenario where I would use NALIRIFOX instead of FOLFIRINOX.

There is no difference in neurotoxicity or response rate. Neurotoxicity was underreported in final publication and response rate overestimated due to lack of B...

This question relates to "unresectable" pancreas cancer. The NAPOLI-3 trial included previously untreated patients with metastatic cancer. At a median follow-up of 16.1 months, median overall survival was 11.1 months with Nalirifox compared to 9.2 months with nab-paclitaxel and gemcitabine. However,...